WO2009096695A2 - Composition cosmétique destinée à soulager le prurit ou l'inflammation, contenant de la daphnétine - Google Patents

Composition cosmétique destinée à soulager le prurit ou l'inflammation, contenant de la daphnétine Download PDF

Info

Publication number
WO2009096695A2
WO2009096695A2 PCT/KR2009/000394 KR2009000394W WO2009096695A2 WO 2009096695 A2 WO2009096695 A2 WO 2009096695A2 KR 2009000394 W KR2009000394 W KR 2009000394W WO 2009096695 A2 WO2009096695 A2 WO 2009096695A2
Authority
WO
WIPO (PCT)
Prior art keywords
daphnetin
lotion
cosmetic composition
itching
cream
Prior art date
Application number
PCT/KR2009/000394
Other languages
English (en)
Korean (ko)
Other versions
WO2009096695A3 (fr
Inventor
Sun One Hwang
Original Assignee
Alphacryptec Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphacryptec Co., Ltd. filed Critical Alphacryptec Co., Ltd.
Publication of WO2009096695A2 publication Critical patent/WO2009096695A2/fr
Publication of WO2009096695A3 publication Critical patent/WO2009096695A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • the present invention relates to a cosmetic composition for improving itching or inflammation, and more specifically, daphnetin (Daphnetin, 7,8-dihydroxycoumarin, CAS No. 486-35-1, having an inhibitory effect on TNF- ⁇ and substance-p secretion). It relates to atopic dermatitis improvement and scalp itching or inflammation improvement cosmetic composition containing Mw 178.44) as an active ingredient.
  • daphnetin Daphnetin, 7,8-dihydroxycoumarin, CAS No. 486-35-1
  • Atopic dermatitis occurs in about 10 to 20% of the entire Korean population, especially in children. After 5 years of age, the incidence decreases, and many adults disappear or alleviate the symptoms. Show the characteristics. As industrialization progresses rapidly, the probability of exposing external stimulants due to a clean living environment is lowered. Accordingly, the number of patients with atopic dermatitis due to the immune system is increasing by more than 10% every year. Although no definite model of the cause of the disease is known, the amount of immunoglobulin E (IgE) increases rapidly and the amount of gamma interferon decreases in atopic dermatitis patients.
  • IgE immunoglobulin E
  • a lipid complex of ceramide to moisturize and restore the skin barrier is applied (Korean Patent Publication No. 2001-0044622), oral administration of antihistamines to treat itching, and steroid preparations for anti-inflammatory
  • problems such as drowsiness due to oral administration of topical and systemic drugs such as steroids, antihistamines and immunosuppressants, lowering of immunity and lowering safety of the skin following topical administration Usage is limited.
  • Inflammatory responses due to activation of PAR-2 are induced through the pathway involving TNF- ⁇ (J. Immumol. 2007, 179 (5), 2910-2917), and itch caused by activation of PAR-2 is associated with CGRP, It is caused by promoting the secretion of Substance-P (TRENDS in Pharmacological Science, 2001, 22 (3), 146-152). Meanwhile, PAR-2 has also been shown to promote the transfer of melanin made from melanocytes (Melanocyte) to the surrounding keratinocytes (Keratinocyte), so the Par-2 inhibitor is also used as a whitening agent.
  • Melanocyte melanocyte
  • Keratinocyte keratinocyte
  • mice knocked out of the PAR-2 gene have been reported to greatly reduce the type 4 contact allergy caused by genes such as fragrance, preservatives, and surfactants (Jpn. J. Pharmacol. 88,77-84 (2002).
  • PAR-2 is involved in scalp itching and contact dermatitis.
  • Korean Patent No. 370455 discloses a composition for improving atopy comprising soy extract, trihydroxy palmitic acid and N-stearoyl-phytosphingosine
  • Korean Patent No. 372682 contains mugwort extract.
  • a cosmetic composition for improving atopic dermatitis Korean Patent Publication No. 2003-32631 discloses a cosmetic composition for treating atopic dermatitis, including plant extracts such as jujube, wood vinegar, aloe and the like.
  • CN20021111231 that daphnetin has an antimalarial effect, but it is distinguished from the present invention.
  • the present invention has been made in accordance with the above requirements, and as a result of repeated studies to develop a material having an effect on atopic dermatitis and scalp itch by improving the itch and reducing inflammation, daphnetin is active PAR-2 Inhibition of secretion of TNF- ⁇ and Substance-P through inhibition of the anti-inflammatory effect and itching suppression effect has been found to improve the atopic dermatitis and scalp itching effect, to complete the present invention.
  • the present invention provides a PAR-2 (Protease-Activated receptor-2) activity inhibitor containing Daphnetin as an active ingredient.
  • the present invention provides a cosmetic composition having an itching or anti-inflammatory effect containing daphnetin as an active ingredient.
  • the cosmetic composition of the present invention was very excellent in atopic dermatitis improvement effect by itching and anti-inflammatory effect.
  • scalp itching effect was also very good and do not cause any side effects
  • daphnetin (Daphnetin) is an excellent atopic dermatitis and scalp itching it can be seen that.
  • the present invention provides a PAR-2 (Protease-Activated receptor-2) activity inhibitor containing Daphnetin as an active ingredient.
  • PAR-2 is activated by serine-proteases such as trypsin and induces secretion of NO and TNF- ⁇ , histamine, Substance-P and calcitonin Gene-Related Peptide (CGRP), leading to inflammation and itching
  • CGRP Gene-Related Peptide
  • the present invention provides a cosmetic composition having an itch improvement effect or anti-inflammatory effect containing daphnetin as an active ingredient.
  • Daphnetin an active ingredient of the cosmetic composition of the present invention, is 7,8-dihydroxycoumarin, and includes Hydrangea macrophylla , Daphne odora , Euphorbia lathyris , Cheongho ( Artemisia apiacea ), and the like. It can be isolated from or artificially synthesized.
  • Daphnetin When Daphnetin was treated with trypsin on HMC-1 cells, which are mast cells, it suppressed the effect of trypsin-induced TNF- ⁇ and substance-p secretion, and applied ophthalmic ointments or cosmetics containing daphnetin When it was prepared and applied to the affected area of atopic patients, itching effect and atopic dermatitis improvement effect was very excellent. In addition, scalp itching effect was also very good and do not cause any side effects, daphnetin (Daphnetin) is an excellent atopic dermatitis and scalp itching it can be seen that.
  • HMC-1 cells which are mast cells
  • the itch may be scalp itch or atopic dermatitis, but is not limited thereto. Itching refers to the condition of the skin that causes discomfort to be scratched. Itching can also be caused by stimuli such as light contact, temperature changes, or stress, or by chemical, physical or electrical stimuli. It is also accompanied by symptoms of skin diseases such as atopic dermatitis, psoriasis, and contact dermatitis, or by sensitive skin holders.
  • the content of daphnetin is suitably 0.00001-10.0% by weight, preferably 0.0001-1.0% by weight, in dry weight, relative to the total weight of the composition. At a concentration below 0.00001% by weight, no obvious effect could be expected. At concentrations above 1.0% by weight, there was no apparent effect increase with increasing content.
  • the cosmetic composition of the present invention is an external skin ointment, cream, supple cosmetics, nourishing cosmetics, pack, essence, hair tonic, shampoo, conditioner, hair conditioner, hair treatment, skin lotion, skin softener, skin toner, astringent, lotion, milk Lotion, moisturizing lotion, nourishing lotion, massage cream, nourishing cream, moisturizing cream, hand cream, foundation, nutrition essence, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser and the like.
  • the composition of each of these formulations may contain a variety of bases and additives necessary for the formulation of the formulation and are suitable, and the types and amounts of these components can be readily selected by those skilled in the art.
  • the formulation of the present invention is a paste, cream or gel
  • animal carriers vegetable fibers, waxes, paraffins, starches, tracantes, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide, etc.
  • carrier components can be used as carrier components.
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
  • a solvent, solvating or emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
  • liquid carrier diluents such as water, ethanol or propylene glycol
  • suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline Cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
  • the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide.
  • Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
  • Examples of prescription external skin ointments containing daphnetin are as follows.
  • a prescription example of a cream in a cosmetic containing Daphnetin is as follows.
  • a prescription example of nutrient cosmetics in cosmetics containing Daphnetin is as follows.
  • the cultured mast cell line HMC-1 was cultured in culture medium IMDM (Iscove's Modified Dulbecco's medium) / FBS (Fetal Bovine Serum) at 5% CO 2 , 37 ° C and aliquoted to 3X10 5 , followed by 10 nM trypsin (final concentration) and daphnetin (Daphnetin). 24 hours later, the amount of TNF- ⁇ in the culture supernatant was investigated as follows by the Enzyme Linked Immunosorbent Assay (ELISA) method.
  • IMDM Iscove's Modified Dulbecco's medium
  • FBS Fetal Bovine Serum
  • Daphnetin can be seen that the inhibition of TNF- ⁇ secretion by trypsin of mast cells. Daphnetin does not show cytotoxicity at 1.0% concentration, and has a very strong TNF- ⁇ secretion inhibitory effect at 0.0001% concentration and can be very useful as an anti-inflammatory agent.
  • the primary human keratinocytes were cultured in serum-free KGM CC-3111 medium (Sanko Junyaku Co.LTD Japan) at 5% CO 2 , 37 ° C to give 1 ⁇ 10 5 cells / cm 2 . Dispense into 6 wells as much as possible and treat 10 nM trypsin (final concentration) and daphnetin to ensure that the cells are full grown, and then competent enzyme immunoassay to investigate the amount of substance-p in the culture supernatant. kit) (Cayman, Ann Arbor, MI) was used, and the amount of substance-p was investigated according to the method proposed in the kit. It summarized in Table 9.
  • the assay method utilizes a competition for binding a free substance-p and a substance-p linked to acetylcholinesterase to a certain concentration of a rabbit antiserum binding site specific for substance-p. How to decide.
  • daphnetin can be seen that strongly inhibit the promotion of substance-p secretion by trypsin of keratinocytes. Daphnetin does not show cytotoxicity at 1.0% concentration, and has a very strong substance-p secretion inhibitory effect at 0.0001% concentration, which can be very useful as an itch inhibitor.
  • the cosmetics containing daphnetin prepared according to Preparation Example 2 was excellent in itching and atopic dermatitis improvement of 85% and 75%, respectively, among the 20 subjects, There are no side effects, indicating that daphnetin is a safe and effective cosmetic for improving itching and atopic dermatitis.
  • the daphnetin-containing hair tonic prepared according to Preparation Example 7 showed an improvement in scalp itch compared to the hair tonic containing no daphnetin, and no side effects were shown, so daphnetin is safe. It is very effective in improving scalp and itching.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un inhibiteur de l'activité du PAR-2 (récepteur 2 activé par une protéase) et une composition cosmétique soulageant efficacement le prurit ou combattant l'inflammation, et contenant de la daphnétine comme composant actif. La composition cosmétique de la présente invention élimine très efficacement le prurit et soulage très efficacement la dermatite atopique. Elle est, de plus, très efficace dans l'élimination des démangeaisons du cuir chevelu, et la daphnétine est un agent utilisé pour éliminer efficacement le prurit ou l'inflammation en cas de dermatite atopique et de dermatite du cuir chevelu sans provoquer de réactions négatives.
PCT/KR2009/000394 2008-01-28 2009-01-28 Composition cosmétique destinée à soulager le prurit ou l'inflammation, contenant de la daphnétine WO2009096695A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0008483 2008-01-28
KR1020080008483A KR20090082619A (ko) 2008-01-28 2008-01-28 다프네틴을 함유하는 가려움증 또는 염증 개선용 화장료조성물

Publications (2)

Publication Number Publication Date
WO2009096695A2 true WO2009096695A2 (fr) 2009-08-06
WO2009096695A3 WO2009096695A3 (fr) 2009-11-26

Family

ID=40913404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/000394 WO2009096695A2 (fr) 2008-01-28 2009-01-28 Composition cosmétique destinée à soulager le prurit ou l'inflammation, contenant de la daphnétine

Country Status (2)

Country Link
KR (1) KR20090082619A (fr)
WO (1) WO2009096695A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8425907B2 (en) 2009-09-09 2013-04-23 Regeneron Pharmaceuticals, Inc. Methods for treating pruritus by administering an antibody that specifically binds human PAR2
CN111773212A (zh) * 2020-08-14 2020-10-16 云南中医药大学 一种瑞香素的应用
CN113712959A (zh) * 2021-09-27 2021-11-30 中山大学附属第一医院 瑞香素在制备防治椎间盘退变药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005306816A (ja) * 2004-04-26 2005-11-04 Pola Chem Ind Inc 夏用の皮膚外用剤
JP2006028094A (ja) * 2004-07-16 2006-02-02 Pola Chem Ind Inc 抗炎症作用を有する皮膚外用剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005306816A (ja) * 2004-04-26 2005-11-04 Pola Chem Ind Inc 夏用の皮膚外用剤
JP2006028094A (ja) * 2004-07-16 2006-02-02 Pola Chem Ind Inc 抗炎症作用を有する皮膚外用剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ERDEM YESILADA ET AL.: 'IN VITRO INHIBITORY EFFECTS OF DAPHNE OLEOIDES SSP. OLEOIDES ON INFLAMMATORY CYTOKINES AND ACTIVITY-GUIDED ISOLATION OF ACTIVE CONSTITUENTS' CYTOKINE vol. 13, no. ISS.6, 2001, pages 359 - 364 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8425907B2 (en) 2009-09-09 2013-04-23 Regeneron Pharmaceuticals, Inc. Methods for treating pruritus by administering an antibody that specifically binds human PAR2
US9028819B2 (en) 2009-09-09 2015-05-12 Regeneron Pharmaceuticals, Inc. Methods of alleviating itch by administering human antibodies to human protease-activated receptor 2
CN111773212A (zh) * 2020-08-14 2020-10-16 云南中医药大学 一种瑞香素的应用
CN113712959A (zh) * 2021-09-27 2021-11-30 中山大学附属第一医院 瑞香素在制备防治椎间盘退变药物中的应用

Also Published As

Publication number Publication date
WO2009096695A3 (fr) 2009-11-26
KR20090082619A (ko) 2009-07-31

Similar Documents

Publication Publication Date Title
US20160067161A1 (en) Cosmetic or pharmaceutical composition for resisting skin ageing through an anti-inflammatory action
US6974596B2 (en) Interleukin-4 production inhibitors
WO2017087640A1 (fr) Traitement probiotique de maladies, troubles et infections cutanés : formulations, procédés et systèmes
WO2011025107A1 (fr) Composition qui permet de soulager le prurit
KR20140055155A (ko) 자외선 등 피부 유해물질로부터 피부를 보호하여 피부 염증 또는 노화를 개선하는 물질 살리드로사이드
WO2009096695A2 (fr) Composition cosmétique destinée à soulager le prurit ou l'inflammation, contenant de la daphnétine
TWI843962B (zh) 用於在敏感性皮膚正常化皮膚微生物群之方法與組成物
WO2018111042A2 (fr) Composition cosmétique comprenant un extrait de plantes médicinales en tant qu'ingrédient actif
KR20170114921A (ko) 피부 건조증 또는 피부 장벽 개선용 조성물 및 항알러지 조성물
JP5154762B2 (ja) インターロイキン６産生抑制剤
KR101611976B1 (ko) 화산석 추출물의 미네랄 복합성분을 유효성분으로 포함하는 피부트러블 개선용 화장료 조성물
KR20120023507A (ko) 유색감자 추출물을 유효 성분으로 함유하는 아토피성 피부염의 개선 또는 치료용 조성물
KR101550727B1 (ko) 피부 염증 및 노화를 개선하기 위한 폴리갈락산 함유 조성물
WO2022092495A1 (fr) Composition pour la prévention, le soulagement ou le traitement d'une maladie immunitaire du type hypersensibilité contenant du galactose
KR20160066186A (ko) 피크리오노시드 a를 함유하는 보습용 조성물
KR20160066185A (ko) 아카리시드 b2를 함유하는 피지 조절 및 모공 축소용 조성물
KR102097834B1 (ko) 7, 8, 4'-트리하이드록시이소플라본을 유효성분으로 함유하는 아토피 피부염 개선용 조성물
WO2024181744A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies cutanées allergiques ou du prurit
WO2022045385A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la repousse des cheveux
WO2020004696A1 (fr) Composition pour l'hydratation et l'apaisement de la peau contenant un extrait végétal
KR102078825B1 (ko) 자외선 등 피부 유해물질로부터 피부를 보호하여 피부 염증 또는 노화를 개선하는 물질 아미그달린
KR20160064500A (ko) 아카리시드 b6을 함유하는 피지 조절 및 모공 축소용 조성물
KR20160064498A (ko) 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 함유하는 피지 조절 및 모공 축소용 조성물
KR20140055969A (ko) 피부 염증 및 노화를 개선하기 위한 테트라메틸피라진 함유 조성물
KR20140055156A (ko) 자외선 등 피부 유해물질로부터 피부를 보호하여 피부 염증 또는 노화를 개선하는 물질 시토스테린

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09706160

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09706160

Country of ref document: EP

Kind code of ref document: A2